D
Arch Biopartners Inc.
ARCH.V
TSX
D
Sell
12/1/2023Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D- from E+ on 12/1/2023 due to a noticeable increase in the solvency index, growth index and valuation index. Operating cash flow increased 160.28% from -$701.1 to $422.6, earnings per share increased from -$0.0114 to -$0.0054, and EBIT increased 44.4% from -$610.6 to -$339.5.
Arch Biopartners Inc. (ARCH.V) was upgraded to D- from E+ on 12/1/2023 due to a noticeable increase in the solvency index, growth index and valuation index. Operating cash flow increased 160.28% from -$701.1 to $422.6, earnings per share increased from -$0.0114 to -$0.0054, and EBIT increased 44.4% from -$610.6 to -$339.5.
E
Sell
6/16/2023Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to E+ from D- on 6/16/2023 due to a large decline in the solvency index, volatility index and total return index.
Arch Biopartners Inc. (ARCH.V) was downgraded to E+ from D- on 6/16/2023 due to a large decline in the solvency index, volatility index and total return index.
D
Sell
3/14/2023Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index, growth index and volatility index. EBIT declined 510.19% from -$258 to -$1.57M, earnings per share declined from -$0.0061 to -$0.0255, and operating cash flow declined 125.35% from $861.9 to -$218.5.
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index, growth index and volatility index. EBIT declined 510.19% from -$258 to -$1.57M, earnings per share declined from -$0.0061 to -$0.0255, and operating cash flow declined 125.35% from $861.9 to -$218.5.
D
Sell
2/23/2023Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D from D- on 02/23/2023.
Arch Biopartners Inc. (ARCH.V) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
2/1/2023Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 2/1/2023 due to a large decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0031 to -$0.0061, EBIT declined 95.75% from -$131.8 to -$258, and the quick ratio declined from 0.73 to 0.21.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 2/1/2023 due to a large decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.0031 to -$0.0061, EBIT declined 95.75% from -$131.8 to -$258, and the quick ratio declined from 0.73 to 0.21.
D
Sell
1/26/2023Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 1/26/2023 due to an increase in the volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 1/26/2023 due to an increase in the volatility index.
D
Sell
1/9/2023Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 1/9/2023 due to a decline in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 1/9/2023 due to a decline in the total return index and volatility index.
D
Sell
8/30/2022Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D+ from C- on 8/30/2022 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 11.22% from $362.8 to $322.1.
Arch Biopartners Inc. (ARCH.V) was downgraded to D+ from C- on 8/30/2022 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 11.22% from $362.8 to $322.1.
C
Hold
3/4/2022Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 3/4/2022 due to a significant increase in the efficiency index and volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 3/4/2022 due to a significant increase in the efficiency index and volatility index.
D
Sell
1/31/2022Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 1/31/2022 due to an increase in the solvency index and volatility index. The quick ratio increased from 0.65 to 0.83, and debt to equity declined from -1.18 to -1.33.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 1/31/2022 due to an increase in the solvency index and volatility index. The quick ratio increased from 0.65 to 0.83, and debt to equity declined from -1.18 to -1.33.
D
Sell
11/23/2021Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and volatility index.
D
Sell
11/8/2021Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index and valuation index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index and valuation index.
D
Sell
2/16/2021Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 2/16/2021 due to a large decline in the total return index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 2/16/2021 due to a large decline in the total return index.
D
Sell
1/29/2021Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 1/29/2021 due to a large increase in the total return index and valuation index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 1/29/2021 due to a large increase in the total return index and valuation index.
D
Sell
1/15/2021Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 1/15/2021 due to a decline in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 1/15/2021 due to a decline in the total return index and volatility index.
D
Sell
11/17/2020Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 11/17/2020 due to an increase in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 11/17/2020 due to an increase in the total return index and volatility index.
D
Sell
10/5/2020Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 10/5/2020 due to a large decline in the growth index and solvency index. EBIT declined 28,272.22% from -$5.4 to -$1.53M, earnings per share declined from -$0.0012 to -$0.0264, and total revenue declined 2.73% from $22 to $21.4.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 10/5/2020 due to a large decline in the growth index and solvency index. EBIT declined 28,272.22% from -$5.4 to -$1.53M, earnings per share declined from -$0.0012 to -$0.0264, and total revenue declined 2.73% from $22 to $21.4.
D
Sell
5/18/2020Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 5/18/2020 due to an increase in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 5/18/2020 due to an increase in the total return index and volatility index.
D
Sell
5/1/2020Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, solvency index and total return index.
C
Hold
3/4/2020Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D on 3/4/2020 due to a significant increase in the efficiency index, growth index and valuation index. EBIT increased 26.86% from -$713.3 to -$521.7, earnings per share increased from -$0.0125 to -$0.0094, and net income increased 24.7% from -$737.6 to -$555.4.
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D on 3/4/2020 due to a significant increase in the efficiency index, growth index and valuation index. EBIT increased 26.86% from -$713.3 to -$521.7, earnings per share increased from -$0.0125 to -$0.0094, and net income increased 24.7% from -$737.6 to -$555.4.
D
Sell
8/30/2019Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 8/30/2019 due to a significant decline in the efficiency index, total return index and valuation index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 8/30/2019 due to a significant decline in the efficiency index, total return index and valuation index.
D
Sell
3/4/2019Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 3/4/2019 due to a significant increase in the efficiency index and valuation index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 3/4/2019 due to a significant increase in the efficiency index and valuation index.
D
Sell
12/10/2018Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 12/10/2018 due to a large decline in the total return index, efficiency index and valuation index. Net income declined 149.34% from -$461.9 to -$1.15M, and total capital declined 2.51% from $927.7 to $904.4.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from D+ on 12/10/2018 due to a large decline in the total return index, efficiency index and valuation index. Net income declined 149.34% from -$461.9 to -$1.15M, and total capital declined 2.51% from $927.7 to $904.4.
D
Sell
3/19/2018Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 3/19/2018 due to a noticeable increase in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D on 3/19/2018 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/2/2018Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D from C- on 3/2/2018 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 72.88% from -$164.8 to -$284.9, earnings per share declined from -$0.0032 to -$0.0049, and net income declined 53.01% from -$175.8 to -$269.
Arch Biopartners Inc. (ARCH.V) was downgraded to D from C- on 3/2/2018 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 72.88% from -$164.8 to -$284.9, earnings per share declined from -$0.0032 to -$0.0049, and net income declined 53.01% from -$175.8 to -$269.
C
Hold
2/21/2018Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 2/21/2018 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 82.67% from -$965.3 to -$167.3, earnings per share increased from -$0.0177 to -$0.0032, and operating cash flow increased 9.35% from -$181.8 to -$164.8.
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 2/21/2018 due to a noticeable increase in the total return index, growth index and volatility index. EBIT increased 82.67% from -$965.3 to -$167.3, earnings per share increased from -$0.0177 to -$0.0032, and operating cash flow increased 9.35% from -$181.8 to -$164.8.
D
Sell
8/31/2017Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D- on 8/31/2017 due to a significant increase in the efficiency index, valuation index and total return index.
Arch Biopartners Inc. (ARCH.V) was upgraded to D+ from D- on 8/31/2017 due to a significant increase in the efficiency index, valuation index and total return index.
D
Sell
6/1/2017Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from C- on 6/1/2017 due to a significant decline in the efficiency index and valuation index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D- from C- on 6/1/2017 due to a significant decline in the efficiency index and valuation index.
C
Hold
5/16/2017Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 5/16/2017 due to an increase in the total return index, volatility index and valuation index.
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 5/16/2017 due to an increase in the total return index, volatility index and valuation index.
D
Sell
5/1/2017Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D+ from C- on 5/1/2017 due to a decline in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D+ from C- on 5/1/2017 due to a decline in the total return index and volatility index.
C
Hold
4/12/2017Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 4/12/2017 due to an increase in the total return index and volatility index.
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D+ on 4/12/2017 due to an increase in the total return index and volatility index.
D
Sell
3/28/2017Downgrade
Arch Biopartners Inc. (ARCH.V) was downgraded to D+ from C- on 3/28/2017 due to a decline in the total return index.
Arch Biopartners Inc. (ARCH.V) was downgraded to D+ from C- on 3/28/2017 due to a decline in the total return index.
C
Hold
3/13/2017Upgraded
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D- on 3/13/2017 due to a significant increase in the efficiency index and valuation index. Net income increased 33.26% from -$264.3 to -$176.4.
Arch Biopartners Inc. (ARCH.V) was upgraded to C- from D- on 3/13/2017 due to a significant increase in the efficiency index and valuation index. Net income increased 33.26% from -$264.3 to -$176.4.
D
Sell
8/31/2016Downgrade
Arch Biopartners, Inc. (ACH.V) was downgraded to D- from D on 8/31/2016 due to a substantial decline in the volatility index and efficiency index.
Arch Biopartners, Inc. (ACH.V) was downgraded to D- from D on 8/31/2016 due to a substantial decline in the volatility index and efficiency index.
D
Sell
3/1/2016Upgraded
Arch Biopartners, Inc. (ACH.V) was upgraded to D from D- on 3/1/2016 due to a substantial increase in the volatility index, total return index and growth index. EBIT increased 21.31% from -$117.8 to -$142.9.
Arch Biopartners, Inc. (ACH.V) was upgraded to D from D- on 3/1/2016 due to a substantial increase in the volatility index, total return index and growth index. EBIT increased 21.31% from -$117.8 to -$142.9.
D
Sell
11/2/2015Upgraded
Arch Biopartners, Inc. (ACH.V) was upgraded to D- from E on 11/2/2015 due to an increase in the efficiency index.
Arch Biopartners, Inc. (ACH.V) was upgraded to D- from E on 11/2/2015 due to an increase in the efficiency index.
E
Sell
8/3/2015Upgraded
Arch Biopartners, Inc. (ACH.V) was upgraded to E from E- on 8/3/2015 due to an increase in the efficiency index.
Arch Biopartners, Inc. (ACH.V) was upgraded to E from E- on 8/3/2015 due to an increase in the efficiency index.
E
Sell
6/2/2015Downgrade
Arch Biopartners, Inc. (ACH.V) was downgraded to E- from E on 6/2/2015 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0062 to -$0.0026, and EBIT declined 54.09% from -$259.2 to -$119.
Arch Biopartners, Inc. (ACH.V) was downgraded to E- from E on 6/2/2015 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0062 to -$0.0026, and EBIT declined 54.09% from -$259.2 to -$119.
E
Sell
5/18/2015None
Arch Biopartners Inc. (ARCH.V) was downgraded to E from U on 05/18/2015.
Arch Biopartners Inc. (ARCH.V) was downgraded to E from U on 05/18/2015.
